Ten women with histories of migraine attacks and with diagnosis of classic or common migraineconcluded a double‐blind, placebo controlled, cross‐over study to assess the effectiveness of syntheticsalmon calcitonin 100 MRC U. i.m. a day in preventing migraine attacks. After a two‐month run‐in phase thewomen were randomly allocated to one of the following two‐month sequences: placebo‐calcitonin orcalcitonin‐placebo. The patients filled in every day a standard card with number, duration and severity ofattacks. The mean migraine frequency per month on calcitonin was 3.7±0.7 (s.e.m.) and on placebo 7.7±1.3(r<0.01). The ratio of total score of headache intensity to the number of days of observation on calcitoninwas 0.18±0.03 and on placebo was 0.30±0.04

Gennari, C., Chierichetti, M.S., Gonnelli, S., Vibelli, C., Montagnani, M., Piolini, M. (1986). Migraine prophylaxis with salmon calcitonin: a cross-over double-blind, placebo-controlled study. HEADACHE, 26(1), 13-16 [10.1111/j.1526-4610.1986.hed2601013.x].

Migraine prophylaxis with salmon calcitonin: a cross-over double-blind, placebo-controlled study

Gennari, C.;Gonnelli, S.;Montagnani, M.;
1986-01-01

Abstract

Ten women with histories of migraine attacks and with diagnosis of classic or common migraineconcluded a double‐blind, placebo controlled, cross‐over study to assess the effectiveness of syntheticsalmon calcitonin 100 MRC U. i.m. a day in preventing migraine attacks. After a two‐month run‐in phase thewomen were randomly allocated to one of the following two‐month sequences: placebo‐calcitonin orcalcitonin‐placebo. The patients filled in every day a standard card with number, duration and severity ofattacks. The mean migraine frequency per month on calcitonin was 3.7±0.7 (s.e.m.) and on placebo 7.7±1.3(r<0.01). The ratio of total score of headache intensity to the number of days of observation on calcitoninwas 0.18±0.03 and on placebo was 0.30±0.04
1986
Gennari, C., Chierichetti, M.S., Gonnelli, S., Vibelli, C., Montagnani, M., Piolini, M. (1986). Migraine prophylaxis with salmon calcitonin: a cross-over double-blind, placebo-controlled study. HEADACHE, 26(1), 13-16 [10.1111/j.1526-4610.1986.hed2601013.x].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/34877
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo